Aurinia Pharmaceuticals (NSDQ:AUPH) announced today that it received a favorable assessment of the cost-effectiveness of Lupkynis. Victoria, British Columbia-based Aurinia’s Lukynis (voclosporin) was evaluated in an independent analysis by the Institute for Clinical and Economic Review (ICER) in a revised evidence report issued on March 12, 2021, according to a news release. The evaluation found […]